Pacific Biosciences Of California (PACB) Income from Continuing Operations (2010 - 2026)

Pacific Biosciences Of California has reported Income from Continuing Operations for 17 years, with the latest figure at -$44.7 million in Q2 2026.

• On a quarterly basis, Income from Continuing Operations fell 6.7% year-over-year to -$44.7 million in Q2 2026; TTM through Jun 2026 was -$131.4 million, a 75.04% increase from a year earlier, with the FY2025 full-year figure at -$546.4 million, down 76.34% from the prior year.
• Income from Continuing Operations was -$44.7 million for Q2 2026 at Pacific Biosciences Of California, down from -$8.3 million in the prior quarter.
• The five-year high for Income from Continuing Operations was $2.4 million in Q4 2024, with the low at -$426.1 million in Q1 2025.
• Average Income from Continuing Operations over 5 years is -$85.0 million, with a median of -$70.6 million recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations surged 102.89% in 2024, then slumped 1802.7% in 2025.
• Over 5 years, Income from Continuing Operations stood at -$84.4 million in 2022, then climbed by 2.8% to -$82.0 million in 2023, then soared by 102.89% to $2.4 million in 2024, then plunged by 1802.7% to -$40.4 million in 2025, then retreated by 10.82% to -$44.7 million in 2026.
• The last three Income from Continuing Operations figures came in at -$44.7 million (Q2 2026), -$8.3 million (Q1 2026), and -$40.4 million (Q4 2025), per Business Quant data.